jRCT ロゴ

臨床研究等提出・公開システム

Top

Japanese

Oct. 30, 2024

Oct. 06, 2025

jRCT2041240115

33-506 :Special Drug Use-Results Survey of OPDIVO (Unresectable advanced or recurrent malignant epithelial tumors excluding squamous cell carcinoma)

33-506 :Special Drug Use-Results Survey of OPDIVO

Nakao Takafumi

Ono Pharmaceutical Co.,LTD

1 -5 Doshomachi 2-chome, Chuo-ku, Osaka-shi, Osaka 541-8526, Japan

+81-6-6222-5501

pms_contact_ml@ono-pharma.com

Nakao Takafumi

Ono Pharmaceutical Co.,LTD

1 -5 Doshomachi 2-chome, Chuo-ku, Osaka-shi, Osaka 541-8526, Japan

+81-6-6222-5501

pms_contact_ml@ono-pharma.com

Recruiting

May. 13, 2024

July. 23, 2024
30

Observational

single arm study

open(masking not used)

uncontrolled control

single assignment

other

Patients with unresectable advanced or recurrent malignant epithelial tumors excluding squamous cell carcinoma, who have recieved OPDIVO for the first time

Patients who have received OPDIVO previously

No limit
No limit

Both

Unresectable advanced or recurrent malignant epithelial tumors excluding squamous cell carcinoma

'[Efficacy]
Comprehensive improvement (the best antitumor efficacy (RECIST) for 6 months after the initiation of OPDIVO or by the end or discontinuation of the treatment)

Ono Pharmaceutical Co.,LTD
Not being included in the items required by GPSP Ordinance, a central IRB is not in place. The study is planned to conduct an IRB at the study site as needed.
none, Ishikawa

July. 10, 2024

No

none

History of Changes

No Publication date
2 Oct. 06, 2025 (this page) Changes
1 Oct. 30, 2024 Detail